What is Brainomix?
Founded in 2010 as a spinout from the University of Oxford, Brainomix specializes in the development of AI-powered software solutions designed to optimize life-saving treatments. The company's flagship e-Stroke platform provides clinicians with a comprehensive suite of imaging tools, enabling rapid interpretation of complex scans and facilitating more confident, data-backed treatment decisions for stroke patients. By bridging the gap between academic research and clinical application, Brainomix has established itself as a vital component of modern neurological care, effectively reducing the time-to-treatment window which is critical for patient outcomes in acute stroke scenarios.
How much funding has Brainomix raised?
Brainomix has raised a total of $52.5M across 5 funding rounds:
Angel/Seed
$1.9M
Series A
$1.6M
Other Financing Round
$9.8M
Series B
$21.2M
Series C
$18M
Angel/Seed (2014): $1.9M with participation from Parkwalk Advisors Limited
Series A (2014): $1.6M led by Chimera Partners and University of Oxford Isis Fund
Other Financing Round (2018): $9.8M supported by Chimera Partners, Boehringer Ingelheim, Parkwalk Advisors, and Oxford University Innovation Fund
Series B (2021): $21.2M featuring Oxford University Innovation Fund, Boehringer Ingelheim Venture Fund, Parkwalk Advisors, and Tencent
Series C (2025): $18M backed by Hostplus, Boehringer Ingelheim Venture Fund, and Parkwalk Advisors
Key Investors in Brainomix
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund invests in pioneering science aimed at redefining care standards and developing new medicines for patients, focusing on first-in-class, disease-modifying therapeutics.
Parkwalk Advisors
Parkwalk is a leading investor in university spinouts, focusing on deeptech innovations emerging from the UK's top universities and bridging the gap between academic research and commercial success.
Hostplus
Hostplus is a prominent Australian national management company for superannuation funds, providing institutional backing to support long-term growth and innovation.
What's next for Brainomix?
With this latest strategic investment, Brainomix is well-positioned to accelerate its global expansion and further refine its AI diagnostic capabilities. The company is expected to focus on scaling its enterprise-level operations, enhancing its software suite to address broader neurological conditions, and deepening its integration within hospital networks worldwide. As the demand for automated, high-precision diagnostic tools continues to rise, Brainomix's ability to leverage its deep-tech expertise and strong investor backing will be pivotal in maintaining its competitive advantage. The focus remains on transforming clinical workflows and ensuring that life-saving interventions are accessible and efficient across diverse healthcare systems.
See full Brainomix company page
